Cargando…

Immunotherapy Using Dendritic Cells against Multiple Myeloma: How to Improve?

Multiple myeloma (MM) is a good target disease in which one can apply cellular immunotherapy, which is based on the graft-versus-myeloma effect. This role of immune effector cells provides the framework for the development of immune-based therapeutic options that use antigen-presenting cells (APCs)...

Descripción completa

Detalles Bibliográficos
Autores principales: Nguyen-Pham, Thanh-Nhan, Lee, Yoon-Kyung, Kim, Hyeoung-Joon, Lee, Je-Jung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3312256/
https://www.ncbi.nlm.nih.gov/pubmed/22481968
http://dx.doi.org/10.1155/2012/397648
_version_ 1782227831503192064
author Nguyen-Pham, Thanh-Nhan
Lee, Yoon-Kyung
Kim, Hyeoung-Joon
Lee, Je-Jung
author_facet Nguyen-Pham, Thanh-Nhan
Lee, Yoon-Kyung
Kim, Hyeoung-Joon
Lee, Je-Jung
author_sort Nguyen-Pham, Thanh-Nhan
collection PubMed
description Multiple myeloma (MM) is a good target disease in which one can apply cellular immunotherapy, which is based on the graft-versus-myeloma effect. This role of immune effector cells provides the framework for the development of immune-based therapeutic options that use antigen-presenting cells (APCs) with increased potency, such as dendritic cells (DCs), in MM. Current isolated idiotype (Id), myeloma cell lysates, myeloma dying cells, DC-myeloma hybrids, or DC transfected with tumor-derived RNA has been used for immunotherapy with DCs. Immunological inhibitory cytokines, such as TGF-β, IL-10, IL-6 and VEGF, which are produced from myeloma cells, can modulate antitumor host immune response, including the abrogation of DC function, by constitutive activation of STAT3. Therefore, even the immune responses have been observed in clinical trials, the clinical response was rarely improved following DC vaccinations in MM patients. We are going to discuss how to improve the efficacy of DC vaccination in MM.
format Online
Article
Text
id pubmed-3312256
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-33122562012-04-05 Immunotherapy Using Dendritic Cells against Multiple Myeloma: How to Improve? Nguyen-Pham, Thanh-Nhan Lee, Yoon-Kyung Kim, Hyeoung-Joon Lee, Je-Jung Clin Dev Immunol Review Article Multiple myeloma (MM) is a good target disease in which one can apply cellular immunotherapy, which is based on the graft-versus-myeloma effect. This role of immune effector cells provides the framework for the development of immune-based therapeutic options that use antigen-presenting cells (APCs) with increased potency, such as dendritic cells (DCs), in MM. Current isolated idiotype (Id), myeloma cell lysates, myeloma dying cells, DC-myeloma hybrids, or DC transfected with tumor-derived RNA has been used for immunotherapy with DCs. Immunological inhibitory cytokines, such as TGF-β, IL-10, IL-6 and VEGF, which are produced from myeloma cells, can modulate antitumor host immune response, including the abrogation of DC function, by constitutive activation of STAT3. Therefore, even the immune responses have been observed in clinical trials, the clinical response was rarely improved following DC vaccinations in MM patients. We are going to discuss how to improve the efficacy of DC vaccination in MM. Hindawi Publishing Corporation 2012 2012-03-15 /pmc/articles/PMC3312256/ /pubmed/22481968 http://dx.doi.org/10.1155/2012/397648 Text en Copyright © 2012 Thanh-Nhan Nguyen-Pham et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Nguyen-Pham, Thanh-Nhan
Lee, Yoon-Kyung
Kim, Hyeoung-Joon
Lee, Je-Jung
Immunotherapy Using Dendritic Cells against Multiple Myeloma: How to Improve?
title Immunotherapy Using Dendritic Cells against Multiple Myeloma: How to Improve?
title_full Immunotherapy Using Dendritic Cells against Multiple Myeloma: How to Improve?
title_fullStr Immunotherapy Using Dendritic Cells against Multiple Myeloma: How to Improve?
title_full_unstemmed Immunotherapy Using Dendritic Cells against Multiple Myeloma: How to Improve?
title_short Immunotherapy Using Dendritic Cells against Multiple Myeloma: How to Improve?
title_sort immunotherapy using dendritic cells against multiple myeloma: how to improve?
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3312256/
https://www.ncbi.nlm.nih.gov/pubmed/22481968
http://dx.doi.org/10.1155/2012/397648
work_keys_str_mv AT nguyenphamthanhnhan immunotherapyusingdendriticcellsagainstmultiplemyelomahowtoimprove
AT leeyoonkyung immunotherapyusingdendriticcellsagainstmultiplemyelomahowtoimprove
AT kimhyeoungjoon immunotherapyusingdendriticcellsagainstmultiplemyelomahowtoimprove
AT leejejung immunotherapyusingdendriticcellsagainstmultiplemyelomahowtoimprove